On Friday, BridgeBio Pharma Inc (BBIO) stock saw a decline, ending the day at $27.33 which represents a decrease of $-0.16 or -0.58% from the prior close of $27.49. The stock opened at $27.84 and ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price upped by HC Wainwright from $43.00 to $49.00 in a research ...
4dOpinion
See the new treatment that will break a Pfizer monopoly on a drug for heart disease.
BridgeBio’s Attruby wins approval for transthyretin amyloid cardiomyopathy while the FDA accepts Alnylam’s application for ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
BridgeBio Pharma (NASDAQ:BBIO – Free Report) had its target price increased by Bank of America from $42.00 to $45.00 in a ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
With approval, acoramaidis (Attruby; BridgeBio Pharma) becomes the first agent with a label specifying near-complete ...
Acoramidis becomes the second drug ever approved for this condition, based on the results of the ATTRibute-CM trial.
(This Nov. 22 story has been corrected to fix the list price of Pfizer's drug to about $268,000, not $225,000, in paragraph 3 ...
In a report released yesterday, Tiago Fauth from Wells Fargo maintained a Buy rating on BridgeBio Pharma (BBIO – Research Report), with a price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback